Lipoproteína: o fator de risco cardiovascular genético negligenciado e as terapias de silenciamento gênico após o resultado do LP Horizon
Lipoprotein is a lipid particle of predominantly genetic origin whose elevated plasma levels are causally and independently associated with the risk of atherosclerotic cardiovascular disease and calcific aortic stenosis. Despite its significant population prevalence an estimated 20% of individuals carry risk-associated concentrations Lp measurement remains absent from most routine cardiovascular screening strategies, constituting a neglected risk factor in clinical practice. This article reviews the pathophysiology of Lp, its genetic determination by the LPA locus, the epidemiological and genetic evidence supporting a causal relationship with cardiovascular outcomes, and the emerging therapeutic landscape. Traditionally, available pharmacological interventions such as statins exert minimal or no effect on Lp. However, the advent of gene-silencing therapies based on antisense oligonucleotides and small interfering RNA represents a paradigm shift. The phase 2 Lp(a)HORIZON trial demonstrated that olpasiran, an ASO targeting apo mRNA, produced dose dependent reductions of up to 80% in Lp levels in patients with established cardiovascular disease, with an acceptable safety profile (Tsimikas et al., 2020). Equally promising results have been observed with the siRNA olpasiran and second-generation compounds. This article argues that recognizing Lp as a legitimate therapeutic target requires a revision of screening guidelines and preparation of clinical practice for the imminent incorporation of these therapies. It is concluded that gene silencing of Lp constitutes the most promising frontier of personalized preventive cardiology, and that the Lp HORIZON result marks the inflection point between historical neglect and causal intervention.
Authors
- Edson da Silva Ribeiro
- Josué Moura Telles (ORCID: https://orcid.org/0009-0002-7526-0387)
- Luís Eduardo da Silva Malta
- Ludymila Cristal Miranda Ferreira
Publication Details
- Journal
- Revista fisio&terapia.
- Published
- 2026-11-18
- DOI
- https://doi.org/10.69849/0k3p4a14
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00